Growing Evidence Shows Promising New Drug to Halt Alzheimer’s Disease in its Tracks
Recent studies have pointed towards the importance of early intervention in treating Alzheimer’s disease. A new drug, NU-9, has shown great promise in slowing down the progression of the disease in its early stages.
Researchers from Northwestern University conducted tests on mouse models of Alzheimer’s and discovered that NU-9 effectively reduces the levels of amyloid beta oligomers, which are toxic protein molecules known to contribute to the development of harmful plaque clumps associated with Alzheimer’s.
By administering NU-9, the researchers observed a significant decrease in the presence of these oligomers in the mouse brains, resulting in healthier astrocytes – the brain support cells crucial for proper brain function.
Neurobiologist William Klein expressed his excitement about the results, stating, “These results are stunning.”
The study not only focused on the impact of NU-9 but also aimed to enhance our understanding of the early stages of Alzheimer’s development, which is vital for the development of new treatments.
The study revealed a previously unidentified subtype of amyloid beta oligomer in the mice, named ACU193+, which attaches to astrocytes in stressed neurons and may trigger neuroinflammation.
Northwestern neuroscientist Daniel Kranz emphasized the importance of early detection and intervention in Alzheimer’s disease, stating, “Alzheimer’s disease begins decades before its symptoms appear.”
While more research is needed to confirm the direct role of amyloid beta in Alzheimer’s, NU-9 has shown promise in preventing oligomer build-up in human brain cells, paving the way for further studies.
Ongoing research is exploring the efficacy of NU-9 in animal models of Alzheimer’s disease in later stages, with the ultimate goal of progressing to human clinical trials for preventative treatment.
If successful, NU-9 could potentially be used as a preventative measure for individuals at high risk of developing Alzheimer’s, similar to cholesterol-lowering drugs for heart disease prevention.
Klein envisions a future where early diagnostic tests for Alzheimer’s combined with NU-9 treatment could halt the disease progression before symptoms manifest.
The findings of the study have been published in Alzheimer’s & Dementia journal.
